Investigational drug study for Treatment of Non-Small Cell Lung Cancer

COVID-19 update:

In response to the COVID pandemic, Scripps Health has either temporarily suspended or limited enrollment with appropriate precautions for all clinical trials. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
IRB-18-7138
Michael P. Kosty, M.D.
This study will test the safety of an experimental drug called atezolizumab given in combination with other chemotherapy drugs. Patients will receive 4 cycles of chemotherapy and undergo surgical removal of their tumor. Some patients may also receive an additional 16 cycles of chemotherapy with atezolizumab.

Inclusion Criteria

  • Be 18 years of age or older
  • Have resectable Stage II, IIA, or Select IIIB Non-small cell lung cancer

Exclusion Criteria

  • Have had any prior therapy for lung cancer, including chemotherapy or radiotherapy
  • Have had any major surgical procedure within 28 days prior to starting study treatment
  • Have any significant heart disease
  • Have a history of cancer other than lung cancer within the last 5 years
  • Be pregnant or nursing

Additional Info

  • Atezolizumab is an investigational immunotherapy drug that is designed to work with the body's own immune system. It may help to activate the immune response and stop a protein called PD-L1 from preventing the body's immune system from fighting cancer.

Contact Info: